ReGen Therapeutics Plc (RGT) - Financial and Strategic Analysis Review by GlobalData

VIEWS: 10 PAGES: 30

More Info
									      ReGen Therapeutics Plc (RGT) - Financial and Strategic Analysis Review

       Reference Code: GDPH81774FSA                                                                                      Publication Date: SEP 2010

       73 Watling Street               Phone            +44 20 71534920                                Revenue           0.0 (million GBP)
       London, ENG                     Fax              +44 20 71534921                                Net Profit        -0.73 (million GBP)
       EC4M 9BJ                        Website          www.regentherapeutics.com                      Employees         6
                                       Exchange                                                        Industry          Pharmaceuticals &
       United Kingdom                                   RGT [SEATS (AIM Market)]
                                                                                                                         Healthcare

      Company Overview
       ReGen Therapeutics Plc (ReGen) is a United Kingdom-based biopharmaceutical company engaged in the development of both
       nutraceutical and ethical healthcare products for age related disorders including Alzheimer’s disease dementia, Parkinson’s
       disease and other degenerative neurological disorders. It focuses on technologies that address large unmet medical need to
       maintain healthy brain ageing as well as rehabilitation after traumatic brain injury. The company operates in two business
       segments: the commercial development and sale of Colostrinin, a proline-rich polypeptide complex derived from mammalian
       colostrum, as a nutraceutical product and the provision of clinical research services.

      Key Executives                                                               SWOT Analysis
                    Name                                 Title                     ReGen Therapeutics Plc, SWOT Analysis
      Percy W. Lomax                      Chairman                                 Strengths                  Weaknesses

      Dr Peter Garrod                     Director
                                                                                   Strong Patent Protection             Declining Market Share
      Norman A. Lott                      Company Secretary
      Martin J. Small                     New Projects Director                    Strong In-House Research             Limited Liquidity Position
                                                                                   Capabilities
      Timothy S. Shilton                  Development Director
      Source: Annual Report, Company Website, Primary and Secondary Research
      GlobalData
                                                                                   Opportunities                       Threats
      Share Data
                                                                                   Emerging Markets                     Product Liability Claims
      ReGen Therapeutics Plc
       Share Price (GBP) as on 08-Sep-                                    0.0      Market Potential – CNS               Uncertain R&D Outcomes
       2010                                                                        Therapy
       EPS (GBP)                                                        -0.03

       Market Cap (million GBP)                                                1
                                                                               1   Source: Annual Report, Company Website, Primary and Secondary Research
 
								
To top